article Open AccessTop 1% cited
Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial
Gut · 2007 · Vol. 56(9) · pp. 1232–1239
William J. Sandborn✉(Mayo Clinic)S. B. Hanauer(University of Illinois Chicago)P. Rutgeerts(Universitair Ziekenhuis Leuven)Richard N. Fedorak(University of Alberta)M Lukas(Charles University)Donald MacIntosh(Dalhousie University)Remo Panaccione(University of Calgary)Douglas C. Wolf(Atlanta Diabetes Associates)Jeffrey D. Kent(Abbott (United Kingdom))Barry Bittle(Abbott (United Kingdom))Li Ju(Abbott (United Kingdom))P Pollack(Abbott (United Kingdom))
Abstract
Adalimumab induced and maintained clinical remission for up to 56 weeks in patients with moderate to severe Crohn's disease naive to anti-TNF treatment.
Inflammatory Bowel DiseaseMicroscopic ColitisEosinophilic EsophagitisAdalimumabMedicineCrohn's diseasePlaceboInternal medicineMaintenance therapySurgeryGastroenterologyClinical trialDisease
MeSH terms
AdalimumabAdultAnti-Inflammatory AgentsAntibodiesAntibodies, MonoclonalAntibodies, AntinuclearCrohn DiseaseDouble-Blind MethodDrug Administration ScheduleDrug Therapy, CombinationFemaleHumansImmunosuppressive AgentsInjections, SubcutaneousLong-Term Care
Funding
- Abbott Laboratories
- Cedars-Sinai Medical Center
Citations
1,030
FWCI
41.49
field-weighted impact
References
34
Percentile
100%
vs. same field & year
Citations per year
Cited by
Guidelines for the management of inflammatory bowel disease in adults
Gut · 2011 · 1,432 citations
Management of Crohn's Disease in Adults
The American Journal of Gastroenterology · 2009 · 1,184 citations
Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms
Clinical Pharmacology & Therapeutics · 2012 · 502 citations
2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis
Annals of the Rheumatic Diseases · 2017 · 1,541 citations
ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update
Annals of the Rheumatic Diseases · 2022 · 832 citations
References
Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial
Arthritis & Rheumatism · 2003 · 1,756 citations
Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM Trial
Gastroenterology · 2006 · 2,237 citations
Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo‐controlled, 52‐week trial
Arthritis & Rheumatism · 2004 · 1,168 citations
Human Anti–Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I Trial
Gastroenterology · 2006 · 1,710 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.